Skip to main content
  1. Home
  2. Emerging Tech
  3. News

The world’s brightest X-ray laser is about to get 10,000 times brighter

Add as a preferred source on Google

Scientists at the Department of Energy’s SLAC National Accelerator Laboratory are preparing to upgrade the lab’s X-Ray laser instrument with a new almost continuous laser that is 10,000 times brighter and 8,000 times faster than the existing Linac Coherent Light Source (LCLS). Construction on the new LCLS-II began this week.

The LCLS pulsed its first laser in April 2009 and is among the most powerful X-ray sources in the world. It is used to record objects at the atomic level with a capture speed in the billionths of a second. Scientists have used the technology to study the forming and breaking of molecular bonds, to track the movement of electrical charges and to generate 3D images of proteins for medical research purposes.

Recommended Videos

The new LCLS-II will generate its extremely bright X-Ray laser beam using electrons that travel nearly the speed of light. This LCLS-II requires the installation of a new superconducting accelerator that uses niobium metal corridors that are refrigerated to -465 degrees Fahrenheit. These lowered temperatures make it possible for the instrument to conduct electricity with zero loss. As the electrons zoom through these corridors, they will allow for an almost continuous X-ray laser beam that pulses up to a million times per second.

The upgraded LCLS-II will be installed alongside the existing LCLS and will be used to continue SLAC’s study of all things fast and small. The brighter and faster laser will make it possible to study chemical, biological and atomic-level processes that are presently not possible with the existing LCLS. “LCLS-II will take X-ray science to the next level, opening the door to a whole new range of studies of the ultrafast and ultrasmall,” said LCLS Director Mike Dunne. “This will tremendously advance our ability to develop transformative technologies of the future, including novel electronics, life-saving drugs and innovative energy solutions.”

Kelly Hodgkins
Kelly's been writing online for ten years, working at Gizmodo, TUAW, and BGR among others. Living near the White Mountains of…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more